GT Biopharma (GTBP) Profit After Tax (2010 - 2026)
GT Biopharma (GTBP) posted quarterly Profit After Tax of -$2.8 million for Q1 2026, down 265.08% year-over-year from $1.7 million in Q1 2025, and up 50.76% quarter-over-quarter from -$5.8 million in Q4 2025.
GT Biopharma (GTBP) Profit After Tax (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Profit After Tax for 17 consecutive years, with -$2.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 265.08% year-over-year to -$2.8 million; the TTM figure through Mar 2026 stood at -$30.5 million (down 160.94% YoY), while the FY2025 annual figure was -$28.4 million, down 115.77% from the prior year.
- Profit After Tax grew to -$2.8 million in Q1 2026 per GTBP's latest filing, from -$5.8 million in the prior quarter.
- Across five years, Profit After Tax topped out at $8.3 million in Q3 2025 and bottomed at -$30.2 million in Q2 2025.
- Historically, Profit After Tax has averaged -$4.3 million across 5 years, with a median of -$3.0 million in 2022.
- Annual changes were most pronounced in 2024 — Profit After Tax plunged 898.24% — and 2025, when it soared 343.3%.
- GT Biopharma's Profit After Tax stood at -$5.6 million in 2022, then soared by 46.96% to -$3.0 million in 2023, then retreated by 27.45% to -$3.8 million in 2024, then sank by 52.42% to -$5.8 million in 2025, then surged by 50.76% to -$2.8 million in 2026.
- Business Quant data shows GTBP's Profit After Tax at -$2.8 million in Q1 2026, -$5.8 million in Q4 2025, and $8.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - | -2.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.83 Mn |
| Dec 31, 2025 | -5.75 Mn |
| Sep 30, 2025 | 8.30 Mn |
| Jun 30, 2025 | -30.17 Mn |
| Mar 31, 2025 | -776,000.00 |
| Dec 31, 2024 | -3.78 Mn |
| Sep 30, 2024 | -3.41 Mn |
| Jun 30, 2024 | -3.71 Mn |
| Mar 31, 2024 | -2.27 Mn |
| Dec 31, 2023 | -2.96 Mn |
| Sep 30, 2023 | -2.42 Mn |
| Jun 30, 2023 | -1.99 Mn |
| Mar 31, 2023 | -227,000.00 |
| Dec 31, 2022 | -5.58 Mn |
| Sep 30, 2022 | -6.88 Mn |
| Jun 30, 2022 | -2.98 Mn |
| Mar 31, 2022 | -5.44 Mn |
| Dec 31, 2021 | -18.02 Mn |
| Sep 30, 2021 | -5.45 Mn |
| Jun 30, 2021 | -4.86 Mn |